Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy
Although immune checkpoint blockade (ICB) has been shown to achieve durable therapeutic responses in various types of tumors, only 20–40 % of patients benefit from this therapy. A growing body of research suggests that epigenetic modulation of the tumor microenvironment may be a promising direction...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024004882 |
| _version_ | 1797328674232467456 |
|---|---|
| author | Xie Xueqing Peng Yongcan Lu Wei Yin Qingling Ding Jie |
| author_facet | Xie Xueqing Peng Yongcan Lu Wei Yin Qingling Ding Jie |
| author_sort | Xie Xueqing |
| collection | DOAJ |
| description | Although immune checkpoint blockade (ICB) has been shown to achieve durable therapeutic responses in various types of tumors, only 20–40 % of patients benefit from this therapy. A growing body of research suggests that epigenetic modulation of the tumor microenvironment may be a promising direction for enhancing the efficacy of immunotherapy, for example, histone methylation plays an important role in the regulation of T cells in the tumor microenvironment (TME). In particular, histone lysine-specific demethylase 1 (LSD1/KDM1A), as an important histone-modifying enzyme in epigenetics, was found to be an important factor in the regulation of T cells. Therefore, this paper will summarize the effects of histone methylation, especially LSD1, on T cells in the TME to enhance the efficacy of anti-PD-1 immunotherapy. To provide a strong theoretical basis for the strategy of combining LSD1 inhibitors with anti-PD-1/PD-L1 immunotherapy, thus adding new possibilities to improve the survival of tumor patients. |
| first_indexed | 2024-03-08T06:55:06Z |
| format | Article |
| id | doaj.art-8ac300e33d3b4563a91f1baefea2c563 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-08T06:55:06Z |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-8ac300e33d3b4563a91f1baefea2c5632024-02-03T06:37:33ZengElsevierHeliyon2405-84402024-01-01102e24457Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapyXie Xueqing0Peng Yongcan1Lu Wei2Yin Qingling3Ding Jie4Guizhou University Medical College, Guiyang, 550025, Guizhou Province, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, ChinaDepartment of Oncology, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550002, ChinaGraduate School of Zunyi Medical University, Zunyi, Guizhou, 563000, ChinaGuizhou University Medical College, Guiyang, 550025, Guizhou Province, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, ChinaDepartment of Gastrointestinal Surgery, Guizhou Provincial People's Hospital, Guiyang, 550002, Guizhou Province, China; Corresponding author. Guizhou Provincial People's Hospital, Nanming District, Guiyang, Guizhou, China.Although immune checkpoint blockade (ICB) has been shown to achieve durable therapeutic responses in various types of tumors, only 20–40 % of patients benefit from this therapy. A growing body of research suggests that epigenetic modulation of the tumor microenvironment may be a promising direction for enhancing the efficacy of immunotherapy, for example, histone methylation plays an important role in the regulation of T cells in the tumor microenvironment (TME). In particular, histone lysine-specific demethylase 1 (LSD1/KDM1A), as an important histone-modifying enzyme in epigenetics, was found to be an important factor in the regulation of T cells. Therefore, this paper will summarize the effects of histone methylation, especially LSD1, on T cells in the TME to enhance the efficacy of anti-PD-1 immunotherapy. To provide a strong theoretical basis for the strategy of combining LSD1 inhibitors with anti-PD-1/PD-L1 immunotherapy, thus adding new possibilities to improve the survival of tumor patients.http://www.sciencedirect.com/science/article/pii/S2405844024004882Tumor microenvironmentCD8+ T cellsHistone methylationLSD1Anti-Tumor immunityAnti-PD-1 |
| spellingShingle | Xie Xueqing Peng Yongcan Lu Wei Yin Qingling Ding Jie Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy Heliyon Tumor microenvironment CD8+ T cells Histone methylation LSD1 Anti-Tumor immunity Anti-PD-1 |
| title | Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy |
| title_full | Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy |
| title_fullStr | Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy |
| title_full_unstemmed | Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy |
| title_short | Regulation of T cells in the tumor microenvironment by histone methylation: LSD1 inhibition—a new direction for enhancing immunotherapy |
| title_sort | regulation of t cells in the tumor microenvironment by histone methylation lsd1 inhibition a new direction for enhancing immunotherapy |
| topic | Tumor microenvironment CD8+ T cells Histone methylation LSD1 Anti-Tumor immunity Anti-PD-1 |
| url | http://www.sciencedirect.com/science/article/pii/S2405844024004882 |
| work_keys_str_mv | AT xiexueqing regulationoftcellsinthetumormicroenvironmentbyhistonemethylationlsd1inhibitionanewdirectionforenhancingimmunotherapy AT pengyongcan regulationoftcellsinthetumormicroenvironmentbyhistonemethylationlsd1inhibitionanewdirectionforenhancingimmunotherapy AT luwei regulationoftcellsinthetumormicroenvironmentbyhistonemethylationlsd1inhibitionanewdirectionforenhancingimmunotherapy AT yinqingling regulationoftcellsinthetumormicroenvironmentbyhistonemethylationlsd1inhibitionanewdirectionforenhancingimmunotherapy AT dingjie regulationoftcellsinthetumormicroenvironmentbyhistonemethylationlsd1inhibitionanewdirectionforenhancingimmunotherapy |